Teva Pharmaceutical Shares Surge 17% After Positive Study Results

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) surged 17% following the announcement of successful Phase 2b study results for its investigational drug duvakitug, aimed at treating inflammatory bowel disease (IBD). The study, conducted in partnership with Sanofi (NASDAQ:SNY), met its primary endpoints for patients with ulcerative colitis (UC) and Crohn’s disease (CD), providing hope for a much-needed new treatment option.

The RELIEVE UCCD study demonstrated that a significant portion of patients with UC and CD treated with duvakitug achieved clinical remission or endoscopic response at week 14 compared to those on placebo. The stock reaction reflects investor optimism regarding the drug's potential market impact, with treatment effects being consistent across patient subgroups.

Eric Hughes, MD, PhD, Head of Global R&D at Teva, expressed confidence in the study's outcomes and potential benefits for patients with IBD. Similarly, Houman Ashrafian, MD, PhD, Executive Vice President at Sanofi, noted duvakitug's potential as a differentiated medication for IBD patients. Both companies commended their collaborative efforts in advancing the drug’s development.

Duvakitug was generally well tolerated, with no significant safety concerns. The rates of treatment-emergent adverse events were similar between the drug and placebo groups, with all reported adverse events under 5%. This favorable safety profile, coupled with positive efficacy data, positions both companies to proceed to the next phase of clinical development.

While the efficacy and safety of duvakitug have not yet been assessed by any regulatory body, the promising Phase 2b results pave the way for further clinical trials. Detailed results are anticipated to be presented at a scientific forum in 2025, providing deeper insights into the drug's market potential and impact on patient care.

Investors will closely monitor the progress of duvakitug as Teva and Sanofi continue their partnership to meet the urgent need for new treatments for ulcerative colitis and Crohn’s disease.

This article was created with the support of AI and reviewed by an editor. For more information, see our T&C.